Skip to content

XOMA Corporation XOMA Asset Acquisition Contingent Value Rights Liability Noncurrent

Asset Acquisition Contingent Value Rights Liability Noncurrent at other companies

WisdomTree logo
WisdomTreeWT
1,440,600,000%
Unusual Machines logo
Unusual MachinesUMAC
$2.85M
Lantheus Holdings logo
Lantheus HoldingsLNTH
$93.98M
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$8.6M-18.2%
Incyte logo
IncyteINCY
$70.62M-53.9%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$5.45M+371%

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept xoma:AssetAcquisitionContingentValueRightsLiabilityNoncurrent.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's asset acquisition contingent value rights liability noncurrent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's asset acquisition contingent value rights liability noncurrent?
XOMA Corporation (XOMA) reported asset acquisition contingent value rights liability noncurrent of $10.89M in Q1 2026.
What does asset acquisition contingent value rights liability noncurrent mean?
This represents the noncurrent liability associated with Contingent Value Rights (CVRs) issued as part of an asset acquisition, which provide the seller with the right to receive additional payments if specific clinical or regulatory milestones are met. It captures the long-term financial exposure related to the success of the underlying drug development programs. This metric is essential for understanding the company's off-balance-sheet-like obligations that become payable upon the achievement of defined therapeutic outcomes.